https://charts.traderzeitung.de/phases/US68062P1066
string(1393) "{"isin":"US68062P1066","name":"Olema Pharmaceuticals inc","stock_id":16776230,"generated_at":"2026-10-11 02:19:00","days":[{"date":"2026-10-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.92,"close_at":"2026-10-07 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-10-08","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.81,"close_at":"2026-10-08 21:59:00","complete":true,"perf_pct":-1.3889},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":7.82,"close_at":"2026-10-08 22:00:00","complete":true,"perf_pct":0.128}]},{"date":"2026-10-09","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.81,"close_at":"2026-10-09 21:59:00","complete":true,"perf_pct":-0.1279},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Olema Pharmaceuticals Aktie News & Nachrichten
Trading-Room

Olema Pharmaceuticals Aktie News & Nachrichten

[WKN: A2QGWT | Symbol: OLMA]
Realtimekurs
   
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Olema Pharmaceuticals

Olema Pharmaceuticals: Bilanzieller Gegenwind trifft auf milliardenschweres Marktpotenzial - Experten sehen bis zu 400 % Kurspotenzial!

Olema Pharmaceuticals (OLMA) beendete das 2. Quartal mit liquiden Mitteln in Höhe von 461,1 Mio. USD,...

Olema Pharmaceuticals: Milliardenmarkt im Visier – Warum Analysten jetzt gewaltige Kurspotenziale sehen

Operative Fortschritte und der Weg zur kommerziellen Phase Olema Pharmaceuticals (OLMA) befindet...

TOP-5-Kursziele der Analysten am 19.03.26

IONOS Group [DE000A3E00M1] Goldman Sachs belässt auf "Buy" - Kursziel weiterhin 45,50 Euro (87 %...

TOP-5-Kursziele der Analysten am 11.12.25

Patrizia [DE000PAT1AG3] Warburg Research bestätigt Buy-Rating und adjustiert das Kursziel von...

Olema Pharmaceuticals: Wachsende Hoffnung auf neue Optionen für resistente Tumoren

Olema Pharmaceuticals richtet seinen Fokus auf neuartige Therapien gegen hormonabhängigen Brustkrebs...

  • ‹
  • 1
  • ›
Olema Pharmaceuticals Nachrichtenticker öffnen
MT Newswires 14.09.2026 13:45 Uhr

Stärkste Verlierer vorbörslich

07:44 AM EDT, 14.09.2026 (MT Newswires) -- Die Aktien von Waldencast (WALD) gaben am Montagmorgen vorbörslich um 41% nach, nachdem das Unternehmen ang

MT Newswires 13.08.2026 14:49 Uhr

Research-Alert: Olema Pharmaceuticals ernennt Jason O'Byrne zum CFO

08:48 AM EDT, 13.08.2026 (MT Newswires) -- Olema Pharmaceuticals (OLMA) teilte am Donnerstag mit, dass Jason O'Byrne zum Chief Financial Officer

MT Newswires 10.08.2026 23:33 Uhr

Olema Pharmaceuticals verzeichnet größeren Verlust im Q2

05:32 PM EDT, 08/10/2026 (MT Newswires) -- Olema Pharmaceuticals (OLMA) meldete am späten Montag einen Nettoverlust im Q2 von 0,61 $ je verwässerter A

MT Newswires 10.08.2026 23:06 Uhr

-- Earnings Flash (OLMA) Olema Pharmaceuticals meldet Q2-Verlust je Aktie von 0,61 USD, verglichen mit der FactSet-Schätzung von 0,55 USD Verlust

05:05 PM EDT, 08/10/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid